Ikena therapeutics

Author: egxx

August undefined, 2024

WebDescription. Developer of an immuno-metabolism therapy technology designed to translate high-impact science into medicines for patients. The company's technology is meant for implementation in human clinical studies for non-oncology indications, enabling doctors to treat cancer patients in a better and hassle-free way. WebIkena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding …

Ikena Oncology Kyn Therapeutics Enters into Global …

WebLearn about the team at Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal ... . Christopher’s Hospital in Philadelphia. Dr. Koehler serves as an independent director on the boards of directors of Ikena Therapeutics and Silverback Therapeutics. Dr. Koehler is a board-certified ... WebAlso Known As Kyn Therapeutics. Legal Name Ikena Oncology, Inc. Stock Symbol NASDAQ:IKNA. Company Type For Profit. Contact Email [email protected]. Phone Number +1 857 273 8343. Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation … hp 14s fq 0026nl

Three Biopharma Companies Making Their Nasdaq Debut

WebFounded Date 2014. Founders Sofie Qiao. Operating Status Active. Last Funding Type Series C. Legal Name Vivace Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel … Web8 dec. 2024 · Michelle Zhang, Ph.D., joined Ikena (then Kyn Therapeutics) in 2016 as Vice President, Research and Development and was later promoted to Senior Vice President, ... Web14 mrt. 2024 · Ikena Oncology : Corporate Presentation - March 2024. We develop differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco- signaling network. Ikena Wholly Owned Pipeline Focused on Targeted Oncology in Hippo-Ras Oncosignaling Network. hp 14s-dq2512sa currys

Ikena Oncology Announces FDA Acceptance of IND Application

Web21 uur geleden · Ikena Oncology. 8,517 followers. 1y. Our president and CEO Mark Manfredi, Ph.D., discussed Ikena’s unique corporate culture and goal to create a vibrant, innovative environment for employees to ... WebIkena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product … hp 14s-fq2000 hddWebIkena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms … Jun 2024 From Ikena Oncology. TRIAL IN PROGRESS: A Phase 1a/b Open Label … At Ikena™, our team is collaborative, passionate about making a difference in … Ikena Oncology is focused on developing novel therapies targeting key signaling … Ikena Oncology Investors Ikena Oncology 645 Summer Street, Suite 101 Boston, MA 02210. Company. … Ikena Oncology may also disclose Aggregate Data in order to describe our … However, Ikena will not release your name or otherwise publicize the fact that you … Ikena is committed to making our website accessible to everyone. We have built … hp 14s-fp2012au

"WebIkena is redefining the targeted oncology landscape and envisioning a world in which every cancer patient has a cure, guided by a deep understanding of the patient experience and … " - Ikena therapeutics

Ikena therapeutics

Kyn to Ikena: The Art and Science of Rebranding - LifeSciVC

Web24 mrt. 2024 · Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. ... Ikena Oncology Financials. Summary financials. Revenue (Q3, 2024)$6.4M Net income (Q3, 2024)($17.3M) Cash (FY, 2024)$59.9M EBIT (Q3, 2024) Web5 sep. 2024 · Arrys Therapeutics: ClinicalTrials.gov Identifier: NCT03658772 Other Study ID Numbers: ARYS-001 Keynote-878 ( Other Identifier: Merck Sharp & Dohme Corp. ) First Posted: September 5, 2024 Key Record Dates: Last Update Posted: April 22, 2024 Last Verified: April 2024

Did you know?

Web5 jan. 2024 · Their stock opened with $16.00 in its Mar 26, 2024 IPO. Ikena Oncology is funded by 12 investors. Bristol Myers Squibb and Cowen Healthcare Investments are the most recent investors. Ikena Oncology has a post-money valuation in the range of $500M to $1B as of Jan 6, 2024, according to PrivCo. Sign up for a free trial to view exact … Web7 mrt. 2024 · Dr. Jeff Ecsedy, Ikena’s Chief Development Officer, will present data supporting the potential of IK-930 as a clinical agent during a minisymposium on experimental and molecular cancer therapeutics.

Web7 okt. 2024 · Pioneering treatments for neurodegenerative diseases. Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source. Atalanta's. branched siRNA. Web7 mrt. 2024 · Ikena is advancing IK-930 both as a monotherapy in patients with Hippo pathway mutated cancers and in combination with other approved targeted therapies to …

Web28 nov. 2024 · Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in a … WebIkena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding what drives their disease. Ikena leverages core capabilities in oncology drug discovery, translational sciences and clinical development to build a next generation ...

Web2 nov. 2024 · Preclinical research, including data presented by Ikena at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2024, suggests that IK-930 is a ...

WebPatient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies … hp 14s fq 1092WebBackground. NTRK fusions are actionable biomarkers with efficient and well tolerated TRKis. Clinical profile and outcomes of pts with NTRK+ tumours receiving non-TRKi SoC are unknown and the prognosis of NTRK+ pts vs pts with NTRK fusion-negative (NTRK–) tumours is not well known. hp 14s dy2508tuWebCedilla’s conditional inhibitors are small molecules that are unlocking historically undruggable cancer targets for therapeutic development. Our asset-by-asset approach is not one-size-fits-all. We start by developing a deep understanding of the disease biology and contextual biochemistry of the target. We then deploy cutting-edge ... hp 14s-fq2000 評価Web17 dec. 2024 · The new name, “Ikena,” is derived from the combination of “i” which refers to the individual patient and “ken” which means knowledge, thereby illustrating our focus on … hp 14s-fq1000WebCompanies include: Tango Therapeutics, Ikena Oncology, Intellia Therapeutics, Solid Bio, Mersana Therapeutics, and Shire. Responsible for full life cycle recruiting for all areas of … hp 14s fq 1092auWebKyn Therapeutics is advancing development programs with targets strongly implicated in immunosuppression across a range of tumor types and via multiple immune cell effects. … hp 14s-fq2000 価格.com限定Web26 mrt. 2024 · Noam Galai/Getty Images. This week began with four biopharma companies announcing intentions to become publicly traded companies and it’s ending with three companies making their debut on the Nasdaq. This morning, two of those companies, Ikena Oncology and Design Therapeutics, join Edgewise Therapeutics by trading on the … hp 14s- fy1005au